# US 6,726,913 B1 · Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,913 B1
- Document ID: US6726913B1
- Status: Granted
- Kind: B1
- Application number: 09/689,621
- Filed: 2000-10-13
- Granted: 2004-04-27
- Earliest claimed: 1999-10-15
- Assignees: The Van Kampen Group, Inc.
- Inventors: Kent R. Van Kampen; Bobby G. Edwards
- Web page: https://patentgrep.com/patent/US6726913B1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Heat-killed, terminally sterilized saline suspensions of Propionibacterium acnes, Propionibacterium avidum, Propionibacterium lymphophilum, Propionibacterium granulosum, Cornynebacterium parvum, and Arachnia propionica are effective in treating viral infections of the respiratory tract in humans, and to induce the regression of dermal tumors and warts in humans. The potency of a saline suspension of heat-killed, terminally sterilized saline suspension of Propionibacterium acnes (P. acnes) was demonstrated through a laboratory animal challenge model. The P. acnes product is administered orally for the purpose of preventing or treating viral infections of the respiratory tract in man. The P. acnes preparation is intralesionally administered into dermal tumors, warts such as plantar warts, or other warts in people caused by the human papilloma virus, to cause regression of such dermal tumors and warts. The subcutaneous route of administration of the P. acnes product causes a systemic reaction that causes long-term warts to completely regress. Anesthetics such as Lidocaine may be added to the P. acnes product to prevent pain upon injection of this immune modulating preparation, while retaining the potency of the P. acnes product. Dose ranges have been established for the oral administration of the P. acnes product to treat viral infections, and for the subcutaneous and intralesional administration of the P. acnes product to treat dermal tumors and warts.

## Claims

### Claim 1

A method of inducing the regression of dermal tumors and warts caused by the human papilloma virus in humans, said method comprising the step of administering a bacterial product comprising heat-killed, terminally sterilized Propionibacterium acnes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the bacterial product comprises heat-killed Propionibacterium acnes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the bacterial product further comprises an anesthetic.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anesthetic is selected from the group consisting of aminoamides and aminoesters.

### Claim 5 (depends on 3)

The method of claim 3, wherein the anesthetic is lidocaine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bacterial product further comprises carriers and fillers.

### Claim 7 (depends on 6)

The method of claim 6, wherein the carriers comprise sugars selected from the group consisting of lactose, saccharose, mannitol, sorbitol, and cellulose preparations.

### Claim 8 (depends on 6)

The method of claim 6, wherein the carriers comprise amino acids.

### Claim 9 (depends on 6)

The method of claim 6, wherein the fillers are selected from the group consisting of starch pastes that use corn, wheat, rice or potato starch, gelatin, methylcellulose, hydroxypropylmethylcellulose, and sodium carboxymethylcellulose.

### Claim 10 (depends on 1)

The method of claim 1, wherein the bacteria are heat-killed by the process of heating the bacteria in a water bath at 74° C. to 90° C. for 60 to 90 minutes.

### Claim 11 (depends on 1)

The method of claim 1, wherein the bacterial product is suspended in a saline solution.

### Claim 12 (depends on 11)

The method of claim 11, wherein the saline solution comprises sodium chloride in deionized water.

### Claim 13 (depends on 11)

The method of claim 11, wherein the saline solution comprises sodium chloride in a buffer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the buffer is selected from the group consisting of alkaline phosphates and alkaline citrates.

### Claim 15 (depends on 1)

The method of claim 1, wherein the bacterial product is administered intralesionally.

### Claim 16 (depends on 1)

The method of claim 1, wherein the bacterial product is administered subcutaneously.

### Claim 17 (depends on 1)

The method of claim 1, wherein the bacterial product is administered at 0.001 to 5 mg per dosage.

### Claim 18 (depends on 1)

The method of claim 1, wherein the bacterial product is administered at 0.005 to 2.5 mg per dosage.

### Claim 19 (depends on 1)

The method of claim 1, wherein the bacterial product is administered at 0.01 to 1 mg per dosage.
